Last reviewed · How we verify
NCT02771405: FRI-STC
Impact of Interferon Free Regimens in Patients With Chronic HCV and Successfully Treated HCC
Phase 3 trial testing Sofosbuvir in Hepatitis C, Chronic in 150 participants. Completed in 1 January 2018.
1 December 2017
Quick facts
| Lead sponsor | National Hepatology & Tropical Medicine Research Institute |
|---|---|
| Phase | Phase 3 |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | non randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 150 |
| Start date | 1 March 2016 |
| Primary completion | 1 December 2017 |
| Estimated completion | 1 January 2018 |
| Sites | 1 location across Egypt |
Drugs / interventions tested
- Sofosbuvir — full drug profile →
- Ribavirin — full drug profile →
- Simeprevir — full drug profile →
- daclatasvir (DACLATASVIR) — full drug profile →
- Ledipasvir — full drug profile →
Conditions studied
- Hepatitis C, Chronic — all drugs for Hepatitis C, Chronic →
- Hepatocellular Carcinoma — all drugs for Hepatocellular Carcinoma →
Sponsor
National Hepatology & Tropical Medicine Research Institute
Who can join
Adults 18 to 70, any sex, with Hepatitis C, Chronic or Hepatocellular Carcinoma. Patients with the condition only — healthy volunteers not accepted.
What's being measured
Primary outcomes are the specific endpoints the trial is designed to prove or disprove.
-
Percentage of Participants With Sustained Virologic Response 12 Weeks After Treatment
Time frame: 12 weeks after the last dose of study drugs
Sponsor's own description
The study will recruit 150 patients with HCV related HCC ,after HCC treatment the patients will undergo treatment with different regimens of DAAs.
Publications & conference data
2 peer-reviewed publications reference this trial (live from Europe PMC):
-
Clinical Perspective of FDA Approved Drugs With P-Glycoprotein Inhibition Activities for Potential Cancer Therapeutics.
Lai JI, Tseng YJ, Chen MH, Huang CF, et al · · 2020 · cited 107× · PMID 33312947 · DOI 10.3389/fonc.2020.561936 -
Hepatitis C virus treatment by direct-acting antivirals in successfully treated hepatocellular carcinoma and possible mutual impact.
Hassany M, Elsharkawy A, Maged A, Mehrez M, et al · · 2018 · cited 16× · PMID 29727383 · DOI 10.1097/meg.0000000000001152
Verify or expand the search:
- PubMed search for NCT02771405
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Sofosbuvir
Trials testing the same drug.
- NCT05717400 — Improving Response to Immunotherapy in Patients With Advanced Hepatocellular Carcinoma and Chronic Hepatitis C Virus Inf · Phase 4 · terminated
- NCT04497649 — Sofosbuvir Containing Regimens in Treatment of COVID 19 Patients · Phase 2, PHASE3 · unknown
- NCT04246723 — Efficacy and Safety of All-Oral Combination of Narlaprevir/Ritonavir and Sofosbuvir in Treatment-naïve Patients With Chr · Phase 2 · completed
- NCT04111367 — Study of Seraprevir in Combination With Sofosbuvir in Chronic Genotype 2,3,6 Hepatitis C Virus Infection Patients · Phase 2 · unknown
- NCT03883698 — Safety of Sofosbuvir in People With Advanced Kidney Failure · Phase 3 · completed
Other recruiting trials for Hepatitis C, Chronic
Currently open trials in the same condition.
- NCT04014179 — Enhancing Hepatitis C Testing and Treatment Among People Who Inject Drugs Attending Needle and Syringe Programs · NA · active not recruiting
- NCT04943588 — Treating Hepatitis C in Pakistan. Strategies to Avoid Resistance to Antiviral Drugs · recruiting
- NCT03520660 — People With CHC Who Achieved a Sustained Virological Response Following Therapy With Direct Acting Antiviral Agents · Phase 4 · active not recruiting
- NCT03200379 — Nation-wide Hepatitis C Virus (HCV) Registry in Taiwan · recruiting
Other National Hepatology & Tropical Medicine Research Institute trials
Trials by the same sponsor.
- NCT07358741 — Standard Two-Day Advanced Life Support (ALS) Versus One Day Recertification Course · recruiting
- NCT07085832 — Assessment of Cardiopumonary Resuscitation (CPR) Competency Post ALS Course · NA · recruiting
- NCT06063993 — Evaluation of Perfusion Index Change Post Passive Leg Raising for Fluid Responsiveness in Critically Ill · completed
- NCT04750135 — Assessment of Metformin as Adjuvant Therapy in Patients With Ulcerative Colitis · Phase 2 · unknown
- NCT04468685 — Ondansetron Effect on Pain Relief After Laparoscopic Cholecystectomy · Phase 2 · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT02771405 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by National Hepatology & Tropical Medicine Research Institute
- Last refreshed: 7 April 2026
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02771405.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing